Andorra vs Fiji: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Andorra
93.0%
in 2025
Fiji
92.0%
in 2025
Andorra rank
51st
Fiji rank
54th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Andorra
- Fiji
How they compare
Andorra currently reports 93.0% against 92.0% in Fiji, a difference of 1.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was Fiji ahead.
Andorra ranks 51st and Fiji ranks 54th of 192 countries.
Fiji has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Andorra | Fiji | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 56.5% | 65.8% | 9.3% | Fiji |
| 2020s | 94.8% | 95.0% | 0.2% | Fiji |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Andorra or Fiji?
- Andorra, at 93.0% against 92.0% in Fiji as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Andorra and Fiji?
- 1.0%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Fiji?
- 18 years are reported by both, from 2008 to 2025.
- How do Andorra and Fiji rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Andorra ranks 51st and Fiji ranks 54th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.